Name (Synonyms) | Correlation | |
---|---|---|
drug2856 | inhaled type I interferon Wiki | 1.00 |
drug2675 | WFI water nebulization Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-19. Currently, there are no effective treatments for the early or late stages of this illness. Governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus. Early data from multiple studies in China, where the virus originated, show that severe cases of CoVID-19 are not as prevalent in patients with chronic lung diseases as expected. This data has been confirmed by the Italian physicians. The investigators think that the widespread use of inhaled corticosteroids reduces the risk of CoVID-19 pneumonia in patients with chronic lung disease. Early microbiological data also shows that these corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells. Inhaled corticosteroids are widely used to manage common lung conditions, such as asthma. This type of medicine is among the top 3 most common medication prescribed around the world. Their safety is well understood, and their potential side effects are mild and reversible. The investigators propose to test this idea that, in participants early in the course of CoVID-19 illness, daily high dose inhaled corticosteroids for 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. We will also study the effect of this inhaled therapy on symptoms and viral load.
Description: Evaluate the effect of intervention on emergency department attendance or hospitalisation related to COVID-19
Measure: Emergency department attendance of hospitalisation related to COVID-19 Time: Day 1 to day 28Description: Evaluate the effect of intervention on body temperature
Measure: Body temperature Time: Day 1 to day 14Description: Evaluate the effect of intervention on blood oxygen level
Measure: Blood oxygen saturation level Time: Day 1 to day 14Description: Evaluate the effect of intervention on patient's symptoms as determined by common cold questionnaire. Higher score meaning worse symptoms.
Measure: Symptoms as assessed by common cold questionnaire Time: Day 1 to day 14Description: Evaluate the effect of intervention on patient's symptoms as determined by FluPro questionnaire. Higher score meaning worse symptoms.
Measure: Symptoms as assessed by FluPro questionnaire Time: Day 1 to day 14Description: Evaluate the effect of intervention on nasal and throat swab SARS-CoV-2 viral load
Measure: Nasal/throat swab SARS-CoV-2 viral load Time: Day 1, 7 and 14